Home > Insider Trading > Filing (0001209191-20-052339)

Filing Details

Accession Number:: 0001209191-20-052339
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-09-29 16:39:56
Reporting Period:: 2020-09-25

Accepted Time:: 2020-09-29 16:39:56
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1699382	Pmv Pharmaceuticals Inc.	PMVP	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Avenue 54Th Floor New York NY 10022	Yes	No	Yes	No
1157524	Orbimed Capital Llc	601 Lexington Avenue 54Th Floor New York NY 10022	Yes	No	Yes	No
1615374	Orbimed Capital Gp V Llc	601 Lexington Avenue 54Th Floor New York NY 10022	Yes	No	Yes	No
1808744	Orbimed Genesis Gp Llc	601 Lexington Avenue 54Th Floor New York NY 10022	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-09-25	475,000	$18.00	475,000	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-09-29	4,025,076	$0.00	4,500,076	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-09-29	1,076,891	$0.00	5,576,967	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-09-29	518,191	$0.00	6,095,158	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-09-29	380,133	$0.00	6,475,291	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-09-29	114,039	$0.00	114,039	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-09-25	475,000	$18.00	475,000	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-09-29	4,025,076	$0.00	4,025,076	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-09-29	1,076,891	$0.00	1,076,891	$0.00
Common Stock	Series C Preferred Stock	Disposition	2020-09-29	518,191	$0.00	518,191	$0.00
Common Stock	Series D Preferred Stock	Disposition	2020-09-29	380,133	$0.00	380,133	$0.00
Common Stock	Series D Preferred Stock	Disposition	2020-09-29	114,039	$0.00	114,039	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The shares are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI V.
This report on Form 4 is jointly filed by OrbiMed Advisors, GP V, OrbiMed Genesis GP LLC ("Genesis GP") and OrbiMed Capital LLC ("OrbiMed Capital"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, Peter Thompson, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors.
The shares of each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.
The shares are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). Genesis GP is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis Master Fund and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
The shares are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of the Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM.